| Q37185876 | A multicenter phase 1 study of PX-866 in combination with docetaxel in patients with advanced solid tumours. |
| Q28731874 | A novel classification of lung cancer into molecular subtypes |
| Q34760642 | A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer |
| Q36872593 | A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer |
| Q45007278 | A randomized, phase II trial of cetuximab with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancer |
| Q28550038 | AKT1E¹⁷K Is Oncogenic in Mouse Lung and Cooperates with Chemical Carcinogens in Inducing Lung Cancer |
| Q57477832 | Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib |
| Q92514240 | Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells |
| Q39656146 | Activation of the phosphoinositide-3-kinase and mammalian target of rapamycin signaling pathways are associated with shortened survival in patients with malignant peritoneal mesothelioma. |
| Q35077627 | Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations. |
| Q38148583 | Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. |
| Q36959707 | Airway PI3K pathway activation is an early and reversible event in lung cancer development |
| Q33411775 | Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines |
| Q37703388 | Alterations of INPP4B, PIK3CA and pAkt of the PI3K pathway are associated with squamous cell carcinoma of the lung |
| Q33708516 | Amplification of chromosomal segment 4q12 in non-small cell lung cancer |
| Q40783190 | An in silico analytical study of lung cancer and smokers datasets from gene expression omnibus (GEO) for prediction of differentially expressed genes |
| Q64237594 | Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland |
| Q49710712 | Antitumor activity of pan-HER inhibitors in HER2-positive gastric cancer. |
| Q38435967 | Best practice in the treatment of advanced squamous cell lung cancer |
| Q54949177 | Beyond EGFR and ALK: targeting rare mutations in advanced non-small cell lung cancer. |
| Q64246368 | C/EBPβ Is a Transcriptional Regulator of Wee1 at the G₂/M Phase of the Cell Cycle |
| Q37714306 | Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents |
| Q36171281 | Cetuximab and biomarkers in non-small-cell lung carcinoma |
| Q28706226 | Characteristics of lung cancers harboring NRAS mutations |
| Q36389868 | Characterization of DDR2 Inhibitors for the Treatment of DDR2 Mutated Nonsmall Cell Lung Cancer |
| Q33509281 | Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study |
| Q36366489 | Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations |
| Q39698149 | Clinical Trials in Non-Small Cell Lung Cancer with Biomarker-Driven Treatment Allocation: Ready or Not, Here We Come |
| Q36671123 | Coexistence of PIK3CA and other oncogene mutations in lung adenocarcinoma-rationale for comprehensive mutation profiling |
| Q35712214 | Comprehensive Molecular Analysis of NSCLC; Clinicopathological Associations |
| Q41606248 | Convergent Akt activation drives acquired EGFR inhibitor resistance in lung cancer |
| Q31096247 | Copy number amplification of the PIK3CA gene is associated with poor prognosis in non-lymph node metastatic head and neck squamous cell carcinoma |
| Q38390024 | Copy number gains of FGFR1 and 3q chromosome in squamous cell carcinoma of the lung |
| Q38242086 | Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer |
| Q34310062 | Current concepts on the molecular pathology of non-small cell lung carcinoma |
| Q28395184 | DNA copy number gains in malignant pleural mesothelioma |
| Q35694415 | De novo discovery of mutated driver pathways in cancer |
| Q38702978 | Decreased phosphatase PTEN amplifies PI3K signaling and enhances proinflammatory cytokine release in COPD. |
| Q47848473 | Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases |
| Q91765967 | Dieckol inhibits non-small-cell lung cancer cell proliferation and migration by regulating the PI3K/AKT signaling pathway |
| Q37008823 | Dissecting the EGFR-PI3K-AKT pathway in oral cancer highlights the role of the EGFR variant III and its clinical relevance. |
| Q28384678 | Divergent genomic and epigenomic landscapes of lung cancer subtypes underscore the selection of different oncogenic pathways during tumor development |
| Q90941054 | Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion |
| Q37634419 | Drug Resistance Mechanisms in Non-Small Cell Lung Carcinoma |
| Q42075208 | Dual Inhibition of PI3K/Akt/mTOR Pathway and Role of Autophagy in Non-Small Cell Lung Cancer Cells |
| Q37382669 | Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations |
| Q28394310 | EGFR-TKI resistance in NSCLC patients: mechanisms and strategies |
| Q36619212 | EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation |
| Q38019719 | EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets |
| Q38607113 | ERK2-dependent reactivation of Akt mediates the limited response of tumor cells with constitutive K-RAS activity to PI3K inhibition |
| Q34460151 | EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors |
| Q47158976 | Econazole nitrate inhibits PI3K activity and promotes apoptosis in lung cancer cells |
| Q37706274 | Effect of 3q oncogenes SEC62 and SOX2 on lymphatic metastasis and clinical outcome of head and neck squamous cell carcinomas. |
| Q36660669 | Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease |
| Q35943089 | Ethnicity affects EGFR and KRAS gene alterations of lung adenocarcinoma |
| Q36262168 | Expression of fibroblast growth factor receptor 1, fibroblast growth factor 2, phosphatidyl inositol 3 phosphate kinase and their clinical and prognostic significance in early and advanced stage of squamous cell carcinoma of the lung |
| Q35117568 | From the bench to bedside: biological and methodology considerations for the future of companion diagnostics in nonsmall cell lung cancer |
| Q48740583 | GLI1 Blockade Potentiates the Antitumor Activity of PI3K Antagonists in Lung Squamous Cell Carcinoma |
| Q36820341 | Gene-expression profiles in lung adenocarcinomas related to chronic wood smoke or tobacco exposure |
| Q36184584 | Genetic and biochemical alterations in non-small cell lung cancer |
| Q36115735 | Genetic changes in squamous cell lung cancer: a review |
| Q26865529 | Genetic characteristics and research progress of targeted therapy in squamous cell carcinoma |
| Q42919827 | Genetic testing for lung cancer: reflex versus clinical selection |
| Q28086993 | Genomic profiling toward precision medicine in non-small cell lung cancer: getting beyond EGFR |
| Q33777454 | Genomics of squamous cell lung cancer |
| Q38153447 | HER2 and lung cancer |
| Q51721747 | High levels of Phosphatase and Tensin Homolog Expression Predict Favorable Prognosis in Patients with Non-small Cell Lung Cancer. |
| Q89666788 | Hypoxia-induced MFAP5 Promotes Tumor Migration and Invasion via AKT Pathway in Head and Neck Squamous Cell Carcinoma |
| Q42221019 | ID1 facilitates the growth and metastasis of non-small cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling |
| Q35947903 | Identification of Gene Expression Differences between Lymphangiogenic and Non-Lymphangiogenic Non-Small Cell Lung Cancer Cell Lines |
| Q36110851 | Identification of SEC62 as a potential marker for 3q amplification and cellular migration in dysplastic cervical lesions |
| Q41657305 | Identification of a subset of human non-small cell lung cancer patients with high PI3Kβ and low PTEN expression, more prevalent in squamous cell carcinoma |
| Q45030586 | Identification of driver mutations in lung cancer: first step in personalized cancer |
| Q57817336 | Identification of genes and analysis of prognostic values in nonsmoking females with non-small cell lung carcinoma by bioinformatics analyses |
| Q36624053 | Identification of potential therapeutic targets for lung cancer by bioinformatics analysis |
| Q28608346 | Identifying Driver Genomic Alterations in Cancers by Searching Minimum-Weight, Mutually Exclusive Sets |
| Q47664459 | Identifying mutual exclusivity across cancer genomes: computational approaches to discover genetic interaction and reveal tumor vulnerability |
| Q33988646 | Impact on disease development, genomic location and biological function of copy number alterations in non-small cell lung cancer. |
| Q36383418 | Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice |
| Q92738799 | In situ growth in early lung adenocarcinoma may represent precursor growth or invasive clone outgrowth-a clinically relevant distinction |
| Q35149263 | Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. |
| Q35174944 | Increased VEGFR-2 gene copy is associated with chemoresistance and shorter survival in patients with non-small-cell lung carcinoma who receive adjuvant chemotherapy |
| Q38852858 | Inhibition of class IA PI3K enzymes in non-small cell lung cancer cells uncovers functional compensation among isoforms |
| Q58766886 | Integrative Bioinformatics Analysis Reveals Potential Long Non-Coding RNA Biomarkers and Analysis of Function in Non-Smoking Females with Lung Cancer |
| Q38322114 | Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer |
| Q37211434 | KRAS Mutation in Small Cell Lung Carcinoma and Extrapulmonary Small Cell Cancer |
| Q53285861 | Low frequency of PIK3CA gene mutations in hepatocellular carcinoma in Chinese population. |
| Q34281228 | Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases |
| Q39027394 | Lung Cancer Biomarkers |
| Q34110617 | Lung Cancer Cell Lines as Tools for Biomedical Discovery and Research |
| Q38679289 | Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development. |
| Q36140332 | Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1. |
| Q37399525 | MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors |
| Q33752376 | Macrophage infiltration and genetic landscape of undifferentiated uterine sarcomas |
| Q53580017 | Maxillary carcinosarcoma: Identification of a novel MET mutation in both carcinomatous and sarcomatous components through next generation sequencing. |
| Q36413157 | Mer or Axl receptor tyrosine kinase inhibition promotes apoptosis, blocks growth and enhances chemosensitivity of human non-small cell lung cancer |
| Q37871213 | Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. |
| Q38203956 | Molecular analysis of cell-free circulating DNA for the diagnosis of somatic mutations associated with resistance to tyrosine kinase inhibitors in non-small-cell lung cancer |
| Q24606677 | Molecular biology of lung cancer |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q43226909 | Molecular diagnostics in lung carcinoma for therapy stratification |
| Q37919395 | Molecular oncology of lung cancer |
| Q33688872 | Molecular pathways and therapeutic targets in lung cancer |
| Q34608584 | Molecular therapeutic advances in personalized therapy of melanoma and non-small cell lung cancer |
| Q47130146 | Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms. |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q28480805 | Multi-level targeting of the phosphatidylinositol-3-kinase pathway in non-small cell lung cancer cells |
| Q34586019 | Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma |
| Q36545440 | Mutant AKT1-E17K is oncogenic in lung epithelial cells |
| Q90744809 | Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitors |
| Q36905878 | Mutations in PI3K/AKT pathway genes and amplifications of PIK3CA are associated with patterns of recurrence in gastric cancers |
| Q38762539 | NEDD4L Protein Catalyzes Ubiquitination of PIK3CA Protein and Regulates PI3K-AKT Signaling |
| Q35667806 | New molecular targeted therapies for advanced non-small-cell lung cancer. |
| Q37080517 | New strategies in squamous cell carcinoma of the lung: identification of tumor drivers to personalize therapy |
| Q36660677 | New targetable oncogenes in non-small-cell lung cancer |
| Q38114835 | New targets in non-small cell lung cancer |
| Q35156742 | Novel candidate key drivers in the integrative network of genes, microRNAs, methylations, and copy number variations in squamous cell lung carcinoma. |
| Q36890658 | Novel compounds in the treatment of lung cancer: current and developing therapeutic agents |
| Q36100771 | Novel therapeutic targets on the horizon for lung cancer. |
| Q26859163 | Nuclear receptor coregulators: modulators of pathology and therapeutic targets |
| Q33510334 | Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells |
| Q38178775 | Oncogenes in non-small-cell lung cancer: emerging connections and novel therapeutic dynamics |
| Q35671281 | Oncogenic KRAS-induced epiregulin overexpression contributes to aggressive phenotype and is a promising therapeutic target in non-small-cell lung cancer |
| Q45916835 | Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages. |
| Q28284802 | Oncogenic mutations of PIK3CA in human cancers |
| Q36671990 | One-pot synthesis of pH-responsive hybrid nanogel particles for the intracellular delivery of small interfering RNA. |
| Q34897198 | P7170, a novel inhibitor of mTORC1/mTORC2 and Activin receptor-like Kinase 1 (ALK1) inhibits the growth of non small cell lung cancer |
| Q35972014 | PI3K Pathway in NSCLC |
| Q35651134 | PIK3CA Amplification Is Common in Left Side-Tubular Adenomas but Uncommon Sessile Serrated Adenomas Exclusively with KRAS Mutation |
| Q92443760 | PIK3CA Gene Mutations in Solid Malignancies: Association with Clinicopathological Parameters and Prognosis |
| Q39050475 | PIK3CA gene mutations and amplifications in Chinese patients with ovarian clear cell carcinoma |
| Q33572680 | PIK3CA gene mutations in Northwest Chinese esophageal squamous cell carcinoma |
| Q37728444 | PIK3CA hypomethylation plays a key role in activation of the PI3K/AKT pathway in esophageal cancer in Chinese patients |
| Q37118223 | PIK3CA mutation in Chinese patients with lung squamous cell carcinoma |
| Q35095308 | PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup |
| Q33987852 | PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers |
| Q35176080 | PIK3CA mutations in non-small cell lung cancer (NSCLC): genetic heterogeneity, prognostic impact and incidence of prior malignancies |
| Q38629644 | PTEN and PI3K/AKT in non-small-cell lung cancer. |
| Q37389526 | Pathogenesis of lung cancer signalling pathways: roadmap for therapies |
| Q28729875 | Personalized pathway enrichment map of putative cancer genes from next generation sequencing data |
| Q37996505 | Personalized therapy for non-small cell lung cancer: which drug for which patient? |
| Q37080513 | Personalizing lung cancer prevention through a reverse migration strategy |
| Q36811453 | Personalizing therapy in advanced non-small cell lung cancer |
| Q35679361 | Personalizing therapy with targeted agents in non-small cell lung cancer |
| Q38248997 | Pharmacotherapy targeting the EGFR oncogene in NSCLC. |
| Q35256618 | Phosphatidylinositol 3-kinase-AKT-mammalian target of rapamycin (PI3K-Akt-mTOR) signaling pathway in non-small cell lung cancer |
| Q34659528 | Plasma RANTES, IL-10, and IL-8 levels in non-small-cell lung cancer patients treated with EGFR-TKIs. |
| Q37853928 | Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway |
| Q37783617 | Potential role of PI3K inhibitors in the treatment of breast cancer. |
| Q36069366 | Primary pulmonary melanoma: a report of two cases |
| Q34775815 | Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma |
| Q33988144 | Progressive 3q amplification consistently targets SOX2 in preinvasive squamous lung cancer |
| Q34460043 | Prospective genetic profiling of squamous cell lung cancer and adenosquamous carcinoma in Japanese patients by multitarget assays |
| Q35733900 | Protein kinase C δ is a downstream effector of oncogenic K-ras in lung tumors |
| Q37438981 | Proteomic markers of DNA repair and PI3K pathway activation predict response to the PARP inhibitor BMN 673 in small cell lung cancer |
| Q34202692 | RAS Interaction with PI3K: More Than Just Another Effector Pathway |
| Q38104414 | Rare mutations in non-small-cell lung cancer |
| Q38514601 | Rationale for targeting the ErbB family of receptors in patients with advanced squamous cell carcinoma of the lung. |
| Q91828934 | Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer |
| Q34678073 | Recent advances in personalized lung cancer medicine |
| Q44483486 | Relevance of genetic alterations in squamous and small cell lung cancer |
| Q24658420 | Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses |
| Q37529904 | Role of PTEN in basal cell derived lung carcinogenesis |
| Q37956397 | Role of genotyping in non-small cell lung cancer treatment: current status |
| Q36284430 | Safety and Efficacy of Buparlisib (BKM120) in Patients with PI3K Pathway-Activated Non-Small Cell Lung Cancer: Results from the Phase II BASALT-1 Study |
| Q36628618 | Screening for major driver oncogene alterations in adenosquamous lung carcinoma using PCR coupled with next-generation and Sanger sequencing methods |
| Q47861831 | Second-line therapy of squamous non-small cell lung cancer: an evolving landscape |
| Q24309044 | Should individual PI3 kinase isoforms be targeted in cancer? |
| Q34170007 | Signaling networks associated with AKT activation in non-small cell lung cancer (NSCLC): new insights on the role of phosphatydil-inositol-3 kinase |
| Q64272437 | Simultaneous inhibition of PI3Kα and CDK4/6 synergistically suppresses KRAS-mutated non-small cell lung cancer |
| Q53298170 | Somatic Mutations in Epidermal Growth Factor Receptor Signaling Pathway Genes in Non-small Cell Lung Cancers |
| Q37800592 | Somatic mutations of signaling genes in non-small-cell lung cancer |
| Q26765060 | Squamous cell carcinomas of the lung and of the head and neck: new insights on molecular characterization |
| Q38048579 | Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy |
| Q55082628 | Subjecting appropriate lung adenocarcinoma samples to next-generation sequencing-based molecular testing: challenges and possible solutions. |
| Q38669277 | Target Therapy in Lung Cancer |
| Q38100162 | Targeted agents in non-small cell lung cancer therapy: What is there on the horizon? |
| Q61455097 | Targeted therapies for advanced non-small cell lung cancer |
| Q36054970 | Targeted therapies for lung cancer: clinical experience and novel agents |
| Q38127728 | Targeted therapy for NSCLC with driver mutations |
| Q37246286 | Targeted therapy in lung cancer: IPASS and beyond, keeping abreast of the explosion of targeted therapies for lung cancer |
| Q37765472 | Targeted therapy in non-small-cell lung cancer--is it becoming a reality? |
| Q37897792 | Targeted therapy of non-small-cell lung carcinoma. |
| Q42369856 | Targeting Novel but Less Common Driver Mutations and Chromosomal Translocations in Advanced Non-Small Cell Lung Cancer |
| Q26861341 | Targeting angiogenesis in squamous non-small cell lung cancer |
| Q37068767 | Targeting genomic alterations in squamous cell lung cancer |
| Q34987170 | Targeting myristoylated alanine-rich C kinase substrate phosphorylation site domain in lung cancer. Mechanisms and therapeutic implications |
| Q89666580 | Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion |
| Q37975242 | Targeting the PI3K signaling pathway in cancer therapy |
| Q92988350 | Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC) |
| Q38157714 | Targeting the protein-protein interaction between IRS1 and mutant p110α for cancer therapy |
| Q35208501 | The BATTLE to personalize lung cancer prevention through reverse migration |
| Q38166599 | The Biological Role of PI3K Pathway in Lung Cancer |
| Q37335920 | The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition |
| Q36510237 | The chromosome 3q26 OncCassette: A multigenic driver of human cancer |
| Q33763006 | The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition. |
| Q40458487 | The effect of IL-1β on synaptophysin expression and electrophysiology of hippocampal neurons through the PI3K/Akt/mTOR signaling pathway in a rat model of mesial temporal lobe epilepsy. |
| Q41891513 | The genomics of lung adenocarcinoma: opportunities for targeted therapies |
| Q36406223 | The introduction of systematic genomic testing for patients with non-small-cell lung cancer |
| Q35749960 | Treatment of nonsmall cell lung cancer: overcoming the resistance to epidermal growth factor receptor inhibitors |
| Q37721218 | Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine |
| Q37510564 | XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer. |
| Q37649231 | YEATS4 is a novel oncogene amplified in non-small cell lung cancer that regulates the p53 pathway. |
| Q53257774 | [Advances on driver oncogenes of lung adenocarcinoma]. |
| Q54350584 | [Advances on driver oncogenes of squamous cell lung cancer]. |
| Q63979899 | [Molecular diagnostics of lung cancer for treatment stratification] |
| Q54329434 | [Research status on molecular targeted therapy for squamous-cell lung cancer]. |
| Q91844986 | mTORC1 inhibitor RAD001 (everolimus) enhances non-small cell lung cancer cell radiosensitivity in vitro via suppressing epithelial-mesenchymal transition |
| Q90351359 | miR-183-5p functions as a tumor suppressor in lung cancer through PIK3CA inhibition |
| Q92617613 | p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas |
| Q33719411 | ΔNp63α is a common inhibitory target in oncogenic PI3K/Ras/Her2-induced cell motility and tumor metastasis |